3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Breast Neoplasms
21
Prostatic Neoplasms
11
Neoplasms
8
Head and Neck Neoplasms
8
Ovarian Neoplasms
6
Oropharyngeal Neoplasms
4
Lung Neoplasms
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Sarcoma
3
Rectal Neoplasms
3
Polycystic Ovary Syndrome
3
Pancreatic Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Squamous Cell
3
Carcinoma, Renal Cell
3
Brain Neoplasms
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Psychological Well-Being
2
Motor Activity
2
Melanoma
2
Kidney Neoplasms
2
Hematologic Neoplasms
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Communication
2
Colonic Neoplasms
2
Central Nervous System Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Interventions
lutetium Lu 177 dotatate
12
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
cabozantinib
5
Everolimus
5
pembrolizumab
4
Nivolumab
4
olaparib
3
lenvatinib
3
Cyclophosphamide
3
177Lu-octreotide, DOTA(0)-Tyr(3)-
3
lanreotide
2
gallium Ga 68 dotatate
2
fludarabine phosphate
2
fludarabine
2
avelumab
2
amino-acid, glucose, and electrolyte solution
2
X-Rays
2
Phantoms, Imaging
2
Octreotide
2
Lutetium-177
2
Ipilimumab
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
tivozanib
1
surufatinib
1
repotrectinib
1
peposertib
1
pazopanib
1
entrectinib
1
belinostat
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroendocrine Tumors
×
Surveys and Questionnaires
×
90 days
×
Clear all
No trials found.